Loading...
XSHE002030
Market cap1.08bUSD
Jan 14, Last price  
5.78CNY
1D
3.03%
1Q
-1.03%
Jan 2017
-51.75%
Name

Daan Gene Co Ltd

Chart & Performance

D1W1MN
XSHE:002030 chart
P/E
75.72
P/S
6.71
EPS
0.08
Div Yield, %
30.99%
Shrs. gr., 5y
—
Rev. gr., 5y
-4.40%
Revenues
1.18b
-90.20%
155,862,029162,471,891172,538,691207,275,582239,204,077319,601,082369,967,649457,560,392582,692,342854,372,3221,086,153,4331,474,339,1021,612,560,4711,542,429,3451,478,663,1281,098,217,1595,341,209,6277,664,262,20212,046,135,0401,180,897,087
Net income
105m
-98.07%
25,199,72026,297,18328,076,64935,036,36639,107,83147,356,35656,452,72868,010,52690,165,000133,275,258153,055,517101,237,343106,685,50486,447,799101,582,97802,449,090,1543,618,186,5645,412,341,064104,659,624
CFO
846m
-79.64%
15,508,76627,797,67430,086,3088,790,31428,969,05054,351,04878,992,10164,537,1633,371,97226,977,09540,377,289000392,378,50992,972,7132,514,511,5293,304,545,7844,154,852,483845,764,161
Dividend
Jun 14, 20240.015 CNY/sh
Earnings
Apr 18, 2025

Profile

Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents and instruments. The company offers fluorescence quantitative PCR products, time resolution series products, enzyme-linked immunoassay products, instrument products, and scientific research service products. It also provides medical examination, and health consultation and management services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. The company was founded in 2001 and is headquartered in Guangzhou, the People's Republic of China.
URL
https://www.daangene.com/
IPO date
Aug 09, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,180,897
-90.20%
12,046,135
57.17%
Cost of revenue
1,253,639
4,940,209
Unusual Expense (Income)
NOPBT
(72,742)
7,105,926
NOPBT Margin
58.99%
Operating Taxes
41,804
891,378
Tax Rate
12.54%
NOPAT
(114,547)
6,214,548
Net income
104,660
-98.07%
5,412,341
49.59%
Dividends
(2,456,031)
(1,557,825)
Dividend yield
18.08%
7.13%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
330,804
157,928
Long-term debt
43,629
134,758
Deferred revenue
27,273
Other long-term liabilities
38,098
29,804
Net debt
(4,621,472)
(3,955,803)
Cash flow
Cash from operating activities
845,764
4,154,852
CAPEX
(572,773)
Cash from investing activities
(129,344)
Cash from financing activities
(2,323,269)
(1,794,639)
FCF
1,082,761
3,637,559
Balance
Cash
2,399,622
3,075,339
Long term investments
2,596,283
1,173,150
Excess cash
4,936,860
3,646,182
Stockholders' equity
9,055,126
11,513,967
Invested Capital
4,610,923
7,911,692
ROIC
100.57%
ROCE
61.23%
EV
Common stock shares outstanding
1,403,446
1,403,446
Price
9.68
-37.79%
15.56
-22.43%
Market cap
13,585,358
-37.79%
21,837,620
-22.43%
EV
9,240,718
18,196,608
EBITDA
284,397
7,404,365
EV/EBITDA
32.49
2.46
Interest
10,042
13,938
Interest/NOPBT
0.20%